LAUSR

Class effects of SGLT2 inhibitors on cardiorenal outcomes

Sign Up to like & get
recommendations!
0 Published in 2019 at "Cardiovascular Diabetology"

DOI: 10.1186/s12933-019-0903-4

Abstract: BackgroundTo summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing… read more here.

Keywords: class effects; credence; canvas; empa reg ... See more keywords